Efficacy of prebiotic supplementation in subjects with GUT DYSBIOSIS
Gut dysbiosis refers to an imbalance in gut microbiota composition and function. Opuntia ficus-indica extract has been shown to modulate gut microbiota by improving of in vivo short-chain fatty acids (SCFA) production and gastrointestinal discomfort (GD) in humans.
Complife team conducted a clinical Study with the aim of demonstrating the efficacy of a supplementation on gastrointestinal health by changing the microbial diversity of species involved in inflammation, immunity, oxidation, and the brain–gut–muscle axis.
The study was a single-center, randomized, double-blind, placebo-controlled, parallel-group trial, conducted at Nutratech S.r.l.
The Complife participant centers involved in the study were:
Nutratech S.r.l. (Rende, Cosenza, Italy),
Complife Italia at CAAD, Center for Translational Research on Autoimmune and Allergic Diseaseand – University of Piemonte Orientale (Novara, Italy)
Complife Italia S.r.l. (San Martino Siccomario, Pavia, Italy).
Complife Italia at CAAD, Center for Translational Research on Autoimmune and Allergic Diseaseand – University of Piemonte Orientale (Novara, Italy)
Complife Italia S.r.l. (San Martino Siccomario, Pavia, Italy).
READ THE COMPLETE STUDY
